Samuel J. Resnick, Seema Qamar, Pushya Krishna, Vlad A. Korben, Hannes Ausserwӧger, Alyssa Miller, Pietro Esposito, Juan A. Varela, Jenny Sheng, Lei Huang, Jonathon Nixon‐Abell, Schuyler Melore, Chyi Wei Chung, Nino F. Läubli, Sofia Kapsiani, Xuecong Li, Jingshu Wang, Nancy R. Zhang, Mahabub Alam, Alondra Schweizer Burguete, Theresa C. Swayne, Yanyan Chen, Ya-Cheng Liao, Neil A. Shneider, Michele Vendruscolo, Tuomas P. J. Knowles, Clemens F. Kaminski, Francesco Simone Ruggeri, Gabriele S. Kaminski Schierle, Peter St George‐Hyslop, Alejandro Chavez
Neurodegenerative disorders (NDDs) are a family of diseases that remain poorly treated despite their growing global health burden. To gain insight into the mechanisms and modulators of neurodegeneration, we developed a yeast-based multiplex genetic screening platform. Using this platform, 32 NDD-associated proteins are probed against a library of 132 molecular chaperones from both yeast and humans, and an unbiased set of ~900 human proteins. We identify both broadly active and specific modifiers of our various cellular models. To illustrate the translatability of this platform, we extensively characterize a potent hit from our screens, the human chaperone DNAJB6. We show that DNAJB6 modifies the toxicity and solubility of multiple amyotrophic lateral sclerosis and frontotemporal dementia (ALS/FTD)-linked RNA-binding proteins (RBPs). Biophysical examination of DNAJB6 demonstrated that it co-phase separates with, and alters the behavior of FUS containing condensates by locking them into a loose gel-like state which prevents their fibrilization. Domain mapping and a deep mutational scan of DNAJB6 revealed key residues required for its activity and identified variants with enhanced activity. Finally, we show that overexpression of DNAJB6 prevents motor neuron loss and the associated microglia activation in a mouse model of FUS-ALS.